Precision BioSciences
A clinical-stage biotechnology company developing in vivo gene editing therapies.
About
Precision BioSciences is a clinical-stage biotechnology company focused on developing in vivo gene editing therapies for genetic diseases. They leverage their proprietary ARCUS genome engineering platform to create novel therapies that aim to correct disease-causing mutations within a patient's own cells. Their lead product candidate, PBCAR0191, is being developed for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia (r/r ALL) and non-Hodgkin lymphoma (NHL). Teams look it up for Biotechnology, Genetics, Pharmaceuticals.
Frequently asked
What does Precision BioSciences do?
Precision BioSciences is a Biotechnology company that offers Platform. Teams look it up for Genetics, Pharmaceuticals, HealthTech. It is based in Durham, North Carolina, USA and was founded in 2006. Public records show about 97 people and $358M raised. Compare it on funding, headcount, reviews and nearby alternatives rather than the marketing line alone.
How much funding has Precision BioSciences raised?
Precision BioSciences has raised a total of $358M in funding. The most recent round on record is Milestone Payment.
Where is Precision BioSciences headquartered?
Precision BioSciences is headquartered in Durham, North Carolina, USA.
When was Precision BioSciences founded?
Precision BioSciences was founded in 2006.
What industry does Precision BioSciences operate in?
Precision BioSciences operates in Biotechnology, Genetics, Pharmaceuticals, HealthTech.
How many employees does Precision BioSciences have?
Precision BioSciences has approximately 97 people on record.
Strength of the site’s backlink profile, on Ahrefs’ 0-100 Domain Rating scale. Licensed third-party data, not our opinion.
How well an AI agent can read and use this site: structured data, clean markup, and whether key facts are reachable without running JavaScript. We scan the live site.
Google PageSpeed mobile performance for the company’s own site. Measured by Google, not by us.